Scholarlink

Objective <p>This study aimed to evaluate the efficacy and safety of secukinumab, an Interleukin-17A (IL-17A) inhibitor, in patients with recurrent spontaneous abortion (RSA) associated with T helper 17 cells / T regulatory cells (Th17/Treg) imbalance.</p> Methods <p>This retrospective cohort study evaluated 108 RSA patients with confirmed Th17/Treg imbalance (Th17/Treg ≥ 0.6 or IL-17A &gt; 4.74&#xa0;pg/mL) at a single center. Patients were divided into secukinumab (<i>n</i> = 54; 3&#xa0;mg/kg subcutaneously plus standard therapy) and control (<i>n</i> = 54; standard therapy alone) groups. Primary outcomes included live birth rate and immunological parameters (Th17/Treg ratio, IL-17A levels), with secondary assessments of neonatal outcomes and safety.</p> Results <p>The secukinumab group demonstrated significantly higher live birth rates (83.33% [45/54] vs 64.81% [35/54]; <i>P</i> = 0.047), with an odds ratio (OR) of 2.71 (95% Confidence Interval (CI): 1.10–6.73), and greater reductions in Th17/Treg ratios (<i>P</i> = 0.010) and IL-17A levels (<i>P</i> = 0.001) compared to controls. No congenital anomalies, maternal or neonatal infections, or treatment-related serious adverse events were observed in either group.</p> Conclusion <p>For RSA characterized by Th17/Treg imbalance, secukinumab demonstrates both clinical efficacy and an acceptable safety profile, suggesting its therapeutic utility.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Secukinumab improves pregnancy outcomes in recurrent spontaneous abortion with T helper 17 cells/T regulatory cells imbalance: a retrospective cohort study

  • 期刊论文

  • 发表日期：

    2025年12月22日

查看全文
  • Guihua Zhu,
  • Xue Wang,
  • Shuqin Bi,
  • Juan Liu,
  • Guiling Yuan,
  • Ning Li,
  • Jinhua Fu,
  • Long Zhao

摘要

Objective

This study aimed to evaluate the efficacy and safety of secukinumab, an Interleukin-17A (IL-17A) inhibitor, in patients with recurrent spontaneous abortion (RSA) associated with T helper 17 cells / T regulatory cells (Th17/Treg) imbalance.

Methods

This retrospective cohort study evaluated 108 RSA patients with confirmed Th17/Treg imbalance (Th17/Treg ≥ 0.6 or IL-17A > 4.74 pg/mL) at a single center. Patients were divided into secukinumab (n = 54; 3 mg/kg subcutaneously plus standard therapy) and control (n = 54; standard therapy alone) groups. Primary outcomes included live birth rate and immunological parameters (Th17/Treg ratio, IL-17A levels), with secondary assessments of neonatal outcomes and safety.

Results

The secukinumab group demonstrated significantly higher live birth rates (83.33% [45/54] vs 64.81% [35/54]; P = 0.047), with an odds ratio (OR) of 2.71 (95% Confidence Interval (CI): 1.10–6.73), and greater reductions in Th17/Treg ratios (P = 0.010) and IL-17A levels (P = 0.001) compared to controls. No congenital anomalies, maternal or neonatal infections, or treatment-related serious adverse events were observed in either group.

Conclusion

For RSA characterized by Th17/Treg imbalance, secukinumab demonstrates both clinical efficacy and an acceptable safety profile, suggesting its therapeutic utility.